Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4;218(1):e20200851.
doi: 10.1084/jem.20200851.

B cells and cancer: To B or not to B?

Wolf Herman Fridman  1 , Florent Petitprez  2 , Maxime Meylan  1 , Tom Wei-Wu Chen  3 , Cheng-Ming Sun  1 , Lubka T Roumenina  1 , Catherine Sautès-Fridman  1
Affiliations

B cells and cancer: To B or not to B?

Wolf Herman Fridman et al. J Exp Med. .

Abstract

Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.

PubMed Disclaimer

Conflict of interest statement

Disclosures: T.W.-W. Chen reported personal fees from Novartis, Roche, Eli Lilly, Daiichi Sankyio, and Eisai outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.
Impact of B cells and TLSs on prognosis and response to ICIs. Analysis of 15 different tumor types. The surface of the spot is proportional to the number of patients for each cancer, with a favorable impact (green), mostly favorable impact (light green), unfavorable impact (red), or no impact (white) on PFS or OS and therapeutic response to ICIs.
Figure 2.
Figure 2.
Mechanisms of action of B cells in cancer. In GCs of TLSs, B cells are selected by antigen presented by FDC-associated immune complexes. They are activated with the help of T follicular helper (Tfh) cells, proliferate, and differentiate into memory B cells and plasma cells. B cells present antigens to CD4 and CD8 T cells. Plasma cells produce IgG antibodies, which may increase antigen presentation to T cells after uptake of immune complexes by DCs and kill or engulf tumor cells via ADCC and ADCP, respectively (right). B cells can also transfer antigen directly to DCs or via complement receptor 2 to FDCs in the form of opsonized immune complexes. Memory B cells and antibodies circulate in the blood, where they help control potential metastatic cells (right). In contrast, binding of immune complexes to macrophages results in their activation and the production of proinflammatory mediators that exert protumor activities. Tumor cell–bound antibodies can also activate complement, which fuels inflammation and activates endothelial cells, promoting tumor growth and spread (left). B reg cells may also inhibit immune responses via the production of IL-10.
See this image and copyright information in PMC

References

    1. Affara N.I., Ruffell B., Medler T.R., Gunderson A.J., Johansson M., Bornstein S., Bergsland E., Steinhoff M., Li Y., Gong Q., et al. . 2014. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 25:809–821. 10.1016/j.ccr.2014.04.026 - DOI - PMC - PubMed
    1. Ager A. 2017. High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function. Front. Immunol. 8:45 10.3389/fimmu.2017.00045 - DOI - PMC - PubMed
    1. Ajona D., Pajares M.J., Corrales L., Perez-Gracia J.L., Agorreta J., Lozano M.D., Torre W., Massion P.P., de-Torres J.P., Jantus-Lewintre E., et al. . 2013. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 105:1385–1393. 10.1093/jnci/djt205 - DOI - PMC - PubMed
    1. Amornsiripanitch N., Hong S., Campa M.J., Frank M.M., Gottlin E.B., and Patz E.F. Jr. 2010. Complement factor H autoantibodies are associated with early stage NSCLC. Clin. Cancer Res. 16:3226–3231. 10.1158/1078-0432.CCR-10-0321 - DOI - PMC - PubMed
    1. Barbera-Guillem E., Nelson M.B., Barr B., Nyhus J.K., May K.F. Jr., Feng L., and Sampsel J.W.. 2000. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol. Immunother. 48:541–549. 10.1007/PL00006672 - DOI - PMC - PubMed

Publication types

Substances